Healios K.K. at the Upcoming Healthcare Conference
Healios K.K. is excited to share that Richard Kincaid, the Chief Financial Officer, will be representing the company at the Jefferies Global Healthcare Conference. This significant event is a platform for Healios to showcase its advancements and innovations in regenerative medicine.
Key Details of the Presentation
During the conference, Richard Kincaid will discuss the progress and future directions of Healios. The presentation is scheduled for:
Date and Time
The presentation is set for a Monday afternoon, where Kincaid will take the stage at 4:00 PM GMT, which translates to 11:00 AM ET. This timing is perfect for those eager to learn about the cutting-edge developments within Healios.
Webcast Information
Interested parties can follow along through a live webcast, which will also be available for viewing afterward for 60 days. This provides an excellent opportunity to catch up on what’s discussed at the event.
Exploring Healios: A Leader in Biotechnology
Healios K.K. stands at the forefront of Japan's biotechnology landscape, specializing in clinical stage advancements that harness the potential of stem cells. Their commitment focuses on creating innovative treatments for patients facing diseases with limited therapeutic options.
Innovative Therapies in Development
Among its various projects, Healios is advancing MultiStem® (HLCM051), a cell product derived from multipotent adult progenitor cells (MAPCs). These cells are known for their anti-inflammatory and immunomodulatory properties, making them suitable for a range of diseases. The positive results from late-stage clinical trials underscore their potential efficacy.
Cancer Treatments with iPS Cells
In addition to MultiStem, Healios has made significant strides with HLCN061, a next-generation NK cell treatment that utilizes iPSC technology. These genetically enhanced cells have shown robust efficacy against tumors in animal models. Healios is collaborating with Akatsuki Therapeutics to bring these treatments to human trials, showcasing their dedication to innovation.
Global Aspirations and Market Presence
Founded in 2011 and listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593), Healios aims to expand its reach globally. The company is actively pursuing advancements in various medical fields, including respiratory conditions and oncology, aiming to address critical unmet medical needs.
Contact Information for Investors
For those interested in learning more about Healios, the U.S. Investor Relations contact is Lisa M. Wilson, reachable at 212-452-2793 or through email. Additionally, Richard Kincaid can be contacted directly regarding investor inquiries.
Frequently Asked Questions
1. What is the focus of Healios K.K.?
Healios focuses on developing innovative regenerative medicine therapies, particularly using stem cells for treating diseases with inadequate treatment options.
2. Where will the presentation take place?
Richard Kincaid will present at the Jefferies Global Healthcare Conference, providing insights into Healios' advancements and strategies.
3. How can I access the webcast?
The live presentation will be available through a webcast, and an archived version will also be accessible for 60 days post-event.
4. What innovative products is Healios developing?
Healios is developing MultiStem®, which focuses on treating various diseases through cutting-edge regenerative techniques, and HLCN061, a promising treatment for cancers.
5. Who should I contact for more information about Healios?
For inquiries, you can contact U.S. Investor Relations, Lisa M. Wilson, or reach out to Richard Kincaid directly for investor-related questions.
